Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 13.8% in May

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 38,000 shares, a drop of 13.8% from the April 30th total of 44,100 shares. Currently, 1.0% of the company's shares are sold short. Based on an average daily trading volume, of 25,800 shares, the days-to-cover ratio is presently 1.5 days.

Monopar Therapeutics Stock Performance

MNPR stock traded down $0.90 during trading on Friday, reaching $37.11. 19,857 shares of the company traded hands, compared to its average volume of 357,894. The company has a market capitalization of $226.93 million, a price-to-earnings ratio of -18.84 and a beta of 1.11. The business has a 50 day simple moving average of $36.89 and a 200 day simple moving average of $33.36. Monopar Therapeutics has a 12 month low of $1.72 and a 12 month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.27. As a group, research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Activity

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the transaction, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the business. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $45,000. Gerber LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $204,000. OMERS ADMINISTRATION Corp purchased a new position in Monopar Therapeutics in the first quarter worth approximately $328,000. Finally, Jane Street Group LLC acquired a new stake in Monopar Therapeutics during the first quarter worth $377,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MNPR has been the topic of a number of recent research reports. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler reissued an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.33.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.